

Ĺ

11-03-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Boyd, Richard

Art Unit:

1623

Serial No.:

10/748,831

Examiner:

TBA

Date Filed:

December 30, 2003

Conf. No.

TBA

Docket Nos.:

NOR-016CP2/286336.155US1

Cust. No.:

23483

Title:

Hematopoietic Stem Cell Gene Therapy

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (Label No. EV507048749US) under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant submits herewith the references on the attached Form PTO-1449. A copy of the PCT Publication No. WO 00/62657 is enclosed; however, copies of the six cited U.S. patent applications are not enclosed. While the six cited U.S. patent applications have not yet published, they are available to the Examiner via the PTO's internal database. Copies of the cited U.S. patent applications can be provided to the Examiner upon his/her request.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (b) (3), before the mailing of a first Office Action on the merits, therefore no fee is due.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be material to patentability. Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicant reserves the right to present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.

.

Supplemental Information Disclosure Statement Appln. No. 10/748,831 Page 2

It is respectfully requested that the Examiner initial and return a copy of the attached Form PTO-1449 with the next Patent Office communication.

No fees are believed to be due in connection with this submission; however, please charge any fees that might be due to Deposit Account Number 08-0219. If there are any questions, the Examiner is invited to call the undersigned at the telephone number indicated below.

Respectfully submitted,

Date: 11 2/04

Ann-Louise Kerner, Ph.D.

Reg. No. 33,523

WILMER CUTLER PICKERING HALE AND DORR LLP 60 State Street Boston, MA 02109 (617) 526-6192 (617) 526-5000 (Facsimile)

Subt. For, PTO-1449 PENFORMATION DISCLOSURE IN AN APPLICATION 1 2 2004 (See several sheets if necessary)

OF

1

Docket Numbers NOR-016CP2/ 286336.155US1 Application Number 10/748,831

Applicant Boyd, Richard

Filing Date December 30, 2003 Group Art Unit 1623

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	10/399,213	N/A	Boyd	N/A	N/A	Apr 14, 2003
	10/748,450	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,118	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,119	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,122	N/A	Boyd	N/A	N/A	Dec 30, 2003
	10/749,120	N/A	Boyd et al.	N/A	N/A	Dec 30, 2003
						•

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/62657	Oct 26, 2000	PCT				

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED			

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.